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Many drug discovery programmes, particularly for infectious diseases, are conducted phenotypically.
Identifying the targets of phenotypic screening hits experimentally can be complex, time-consuming,
and expensive. However, it would be valuable to know what the molecular target(s) is, as knowledge
of the binding pose of the hit molecule in the binding site can facilitate the compound optimisation.
Furthermore, knowing the target would allow de-prioritisation of less attractive chemical series or
molecular targets. To generate target-hypotheses for phenotypic active compounds, an in silico platform
was developed that utilises both ligand and protein-structure information to generate a ranked set of
predicted molecular targets. As a result of the web-based workﬂow the user obtains a set of 3D structures
of the predicted targets with the active molecule bound. The platform was exempliﬁed using Myco-
bacterium tuberculosis, the causative organism of tuberculosis. In a test that we performed, the platform
was able to predict the targets of 60% of compounds investigated, where there was some similarity to a
ligand in the protein database.
© 2019 Published by Elsevier Inc.1. Introduction
Phenotypic drug discovery is a powerful way to conduct drug
discovery programmes [1,2], particularly in the area of infectious
diseases, where there are very few well-validated molecular tar-
gets. Phenotypic drug discovery does not necessarily pre-suppose a
given target or pathway. The advantage of phenotypic screening is
that compounds that are active in phenotypic screening modulate a
mechanism(s) or pathway that is essential for the survival of the
organism. In addition, these compounds have the correct proper-
ties for permeation through the cellular envelope, are metabolically
stable in the infectious organism and access the molecular target(s)
without signiﬁcant efﬂux, which is a major problem in certain
disease areas such as tuberculosis (TB) and Gram-negative bacteria.
Due to the poor compound permeation, compound metabolism
and to the presence of efﬂux, it can be in fact difﬁcult to achieve the
required compound exposure within a cell. Often target-based
approaches fail due to low intracellular compound levels.
However, one of the major limitations of phenotypic drugert).
l., A platform for target pred
016/j.jmgm.2019.107485discovery is lack of knowledge of the molecular target and the
binding mode of the hits within the target. Such knowledge could
enable a structure-guided approach leading to a focused medicinal
chemistry programme. Further, many phenotypic projects are
halted by issues connected with the chemical scaffold of the active
series, such as poor pharmacokinetics or toxicological problems.
Knowledge of the binding mode of the compound to the target
protein would greatly facilitate “scaffold hopping” [3,4] to
circumvent these issues. Additionally, some proteins and pathways
are more attractive drug targets than others, and knowledge of the
target will help to prioritise which hits should be progressed.
Compounds often interact with multiple proteins [5]; knowing
potential additional targets of a compound is important in com-
pound optimisation. However, determining the targets of hit mol-
ecules from phenotypic screens experimentally can be complex,
expensive, time-consuming and not always successful. Therefore,
being able to predict targets computationally would be highly
beneﬁcial, as it could provide hypotheses to be tested
experimentally.
As part of our effort to identify better treatments for tubercu-
losis we are actively involved in a number of phenotypic drug
discovery projects. During the past few years we have carried out
several phenotypic high throughput screening campaigns testingiction of phenotypic screening hit molecules, Journal of Molecular
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chemical series. In this paper, we report the development of an in
silico platform that is able to produce target hypotheses for
phenotypic actives against Mycobacterium tuberculosis (M. tb.). The
approach utilises both the structure of the active hit compound and
the part of the M. tb. proteome for which a crystal structure is
available or that can be modelled with a high degree of conﬁdence.
The 2D chemical structure of the phenotypic hit of interest is the
initial input, the output is a set of ranked potential targets, and for
each target, relevant binding poses are generated.
During the last 15 years, a number of computational target
identiﬁcation algorithms have been developed [6e20]. Many of
them are based on the similarity of hit molecules to other com-
pounds for which targets are known [6e11]. Some algorithms take
advantage of data mining or machine learning methods [7,20] to
perform extensive data mining and search for compounds that are
similar to the active ones [12,13,20,21]. Other approaches use the
similarity in bio-activity spectra or transcriptional proﬁles for
target prediction [14,15]. An example of a TB-speciﬁc approach is
fromMartínez-Jimenez et al. 2013 [22], who performed a network-
based target prediction for a large set of M. bovis and M. tb.
phenotypic screening hits from an analysis of GlaxoSmithKline
[22]. Some methods explicitly take the 3D properties of the target
into account. These can be based on large collections of pharma-
cophore models derived from the binding sites of known targets
[16]. Alternatively reverse docking approaches have been devel-
oped where the hit molecule is docked into a large number of
possible target structures [17e19,23,24]. These 3D approaches are
highly computationally demanding, and calculation runtimes can
be a major bottleneck. They are also limited by the number of 3-
dimensional protein structures available [18,25]. For example, in
May 2017 there were 554 unique proteins from M. tb. in the PDB
[26] which corresponds to only about 13% of the M. tb. proteome.
Homologymodels have been produced of theM. tb. proteome; as an
example the CHOPIN database [27].
The approach that we describe here was designed to generate
hypotheses of potential targets of phenotypic hits and their po-
tential binding modes within the protein, utilising the structure of
both the ligand and targets.
2. Outline of approach
The binding of a small molecule to the site of a protein target can
be seen as a molecular recognition event where the ligand will be
anchored into the protein active site through key interactions be-
tween the ligand and protein, such as hydrogen bonds, dipole-
dipole, p-stacking and hydrophobic interactions. These speciﬁc
interactions deﬁne a molecular pharmacophore.
The premise of our approach is that structurally similar com-
pounds interacting through a similar pharmacophore will be
recognized by a similar protein binding site. Given a phenotypic hit
molecule, if we could identify a related compound with a very
similar pharmacophore bound to a speciﬁc protein site in the
Protein Databank (PDB) [28], thenwe could use that information to
identify in M. tb. any protein that has a similar binding site and
further explore the binding of the phenotypic hit to that binding
site to formulate target hypotheses.
Despite the increasing number of structures deposited in the
PDB the number of small molecules bound to a protein binding site
in the PDB covers a limited amount of chemical space (there are
26,672 small molecule ligands in the PDB, Nov 2018). This reduces
the chances of identifying a small molecule ligand in the PDB that is
similar to the molecular hit identiﬁed by the phenotypic screening.
The fragment-based drug discovery approaches developed in
the past 20 years [29] have shown that working in a low molecularPlease cite this article as: N. Homeyer et al., A platform for target pred
Graphics and Modelling, https://doi.org/10.1016/j.jmgm.2019.107485complexity space greatly increases the efﬁciency of the sampling of
the chemical space and that fragment hits can be identiﬁed even
when libraries smaller than typical HTS libraries are screened. By
analogy to the fragment-based drug discovery process, we have
fragmented all the small molecule ligands in the PDB and created a
database capturing, for each fragment, the speciﬁc sub-pocket that
recognizes the fragment itself and the speciﬁc interactions it es-
tablishes with the protein. We then reduced the molecular
complexity of the phenotypic hit by fragmenting its chemical
structure to generate in silico a set of related molecular fragments.
These fragments from the phenotypic hit can then be compared to
fragments from the PDB small molecule ligands.
Following an experimental screening campaign, as part of our
hit evaluation process, we normally generate and test a small
number of close analogues in order to gain an understanding of the
relevance of the functional groups and formulate a ﬁrst hypothesis
of the minimum pharmacophore associated to the biological
response. This knowledge can be used to select one or more in silico
fragments generated from the initial phenotypic hit, to start the
target hypothesis generation process. The ﬁrst step is the identiﬁ-
cation of the fragment in the PDB that is either identical or most
similar to the fragment representing the phenotypic active. This
fragment will deﬁne a pocket in the PDB structure and a set of
interactions that should be coherent with the initial
pharmacophore.
The next step is to see if there is a similar pocket or sub-pocket
within the pathogen (M. tb.) proteome to that found in the PDB.
This pocket or sub-pocket should bind the “fragment” of the
phenotypic active in a similar manner to that observed in the PDB.
As a check, we aim to reﬁt the entire phenotypic active compound
into the pocket, and to verify if this putative binding mode in the
putative target can explain any observed SAR. The applicability of
this approach can be limited by the fact that the PDB contains a
relatively small number of crystal structures from any given path-
ogen (in this case M. tb.). To address this problem, we created a
database of high conﬁdence M. tb. modelled structures covering a
larger portion of the M. tb. proteome. The overall concept is out-
lined in Fig. 1.3. Workﬂow of the target prediction platform
Before starting the process, there were some key preparative
steps. Firstly, the PDB ligands were fragmented to provide a data-
base of fragments (PDB fragment space). The ligands were frag-
mented to generate as many molecular fragments as possible, to
ensure that as many pharmacophoric patterns as possible are
captured (see Supporting Information S1A). For each fragment a
binding cavity is then deﬁned and the fragment-protein in-
teractions analyzed. We also needed to generate a M. tb. target
space (more than 5700 structures in total) including the existing
M. tb. structures in the PDB (2,055 structures) and a set of high-
quality M. tb. modelled protein structures (3,667 structures),
which were generated using Rosetta [31]. (see Supporting
Information S2). We initially generated homology models for all
the proteins encoded in the proteome, but only including in the
M. tb. target space those models built on highly homologous tem-
plate structures, which meant that not all M. tb. proteins were
represented in our database. The Rosetta homology modelling was
setup to generate homo- and hetero-oligomers whenever data
were available. For each structure/model, the molecular surface
was analyzed to identify potential binding cavities.
The platform workﬂow starts with the input of the
phenotypically-active compound and consists of four main steps
(Fig. 1).iction of phenotypic screening hit molecules, Journal of Molecular
Fig. 1. Schematic depiction of the workﬂow of the target prediction platform starting from the input of the hit molecule and ending with the output of the hit-target complex. The
example hit molecule was taken from He et al. 2008 [30].
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GStep 1: Fragmentation of phenotypic active. The active hit
molecule is split into fragments in such a way that the phar-
macophoric features of the molecule are maintained (see Sup-
porting Information S1A). The user selects which fragments of
the hit compound are used as input (fragment query). The more
structure-activity relationship data that are known for the
phenotypically active molecule, the better the user is able to
select a fragment query that contains those chemical features
that are essential for activity, to use for the database search.
Step 2: Fragment Matching. A search is carried out to see if the
fragment query maps to the PDB fragment space. If there is no
direct match, a similarity search can be conducted. Two different
options are available to search for similar fragments. Firstly, an
exact / similarity substructure search identiﬁes fragments that
are identical or that have a highly similar structure. Secondly, an
algorithm has been developed which allows detection of frag-
ments with a similar connectivity and element composition, butease cite this article as: N. Homeyer et al., A platform for target predict
raphics and Modelling, https://doi.org/10.1016/j.jmgm.2019.107485not necessarily a similar substructure (see Supporting Infor-
mation S1B).
Step 3: Cavity Comparison. When an exact match or a similar
fragment for the fragment query is identiﬁed in the PDB frag-
ment space, the binding cavity for the fragment in the PDB is
retrieved. The identiﬁed fragment cavity is used as query in a
cavity comparison search to identify in the M.tb. target space
structures with a similar binding pocket. M. tb. proteins with
binding sites that are highly similar to the binding site that
recognizes the query fragment in the PDB can be considered as
potential targets of the phenotypically active molecule. Four
different cavity comparison algorithms have been implemented
in the platform: BioGPS [32e34], SubCav [35], FuzCav [36],
aCSM [37] (see Supporting Information S2).
Step 4: As a validation step, the “original” phenotypically active
molecule is docked into the binding site of the M. tb. protein
identiﬁed as potential target. This step can help to identify false
positives, if either the phenotypic active does not ﬁt in the activeion of phenotypic screening hit molecules, Journal of Molecular
Fig.
in o
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Gsite or the binding mode does not explain any observed SAR.
Restraints can be used for the docking step to try and match the
proposed binding mode and binding interactions of the
phenotypic active (see Supporting Information S1D). The bind-
ing site of the hit and the docking result can be visually
inspected in a molecular viewer [38]. In addition, the complex
can be downloaded in PDB format and in formats optimized for
the viewers, Pymol [39], Maestro [40], and ICM Browser [38].4. Architecture of the target prediction platform
The target prediction platform is accessible via a web-interface
which is build based on the python package Flask [39] and the
development server integrated therein. Template ﬁles for rendering
the webpages are written in HTML (Fig. 2, green). Applications and
associated scripts are written in python (Fig. 2, blue). The applica-
tions access databases created for the platform, containing infor-
mation about PDB structures and the modelled M. tb. structures
(Fig. 2, red). Other data are directly stored on disc and accessed
from there (Fig. 2, black). In addition, the different programs (Fig. 2,
orange) are called from the applications. Some applications were
written in house, based on OpenBabel [41]: the fragmentation
program iChopþþ, the similarity search program SimFrag, and the
program scaffoldjump that are written in Cþþ. Additional external
programs are also in the pipeline: BioGPS [32e34], SubCav [35],
FuzCav [36], aCSM [37], LigPrep [42], and Glide [42e45]. The
conﬁguration of the system including the speciﬁcation of database
access as well as of all input and output paths is managed in a2. Schematic depiction of the architecture of the target identiﬁcation platform. Arrows s
range, italic writing, whereas programs written for the purpose of the platform are given
er is referred to the Web version of this article.)
ease cite this article as: N. Homeyer et al., A platform for target pred
raphics and Modelling, https://doi.org/10.1016/j.jmgm.2019.107485centrally stored ﬁle conﬁg.py. Therefore, the system can be easily
setup in another computing environment.5. The web-interface
In order to make the platform as user-friendly as possible, we
generated a workﬂow that can be operated via a web-interface. It
has been designed for use by medicinal chemists, who may not be
experts in modelling, but can interpret both small molecule and
protein structures. The front end of the applications is a set of
clearly structured webpages (Fig. 3). On the ﬁrst page (step 0) the
user can draw or upload the phenotypically active molecule. After
the fragmentation (step 1) a webpage with the fragments is shown
to the user. The fragments are displayed in white rectangles within
a grey box. They can be sorted by pressing the buttons “Mol.
weight”, “Num. of heavy atoms”, “Num. bonds”, and “Num. rotors”
above the grey box (Fig. 3, top right image). In addition, the frag-
ments can be ﬁltered bymolecular weight. It is also possible to only
show those fragments that fulﬁll the rule of three or that do not
fulﬁll the rule of three by clicking on the “Is rule of 3” or “Is not rule
of 3” buttons. Using this functionality, it is easy to inspect the ob-
tained fragments and ﬁnd fragments with the desired properties.
The more information that is known about the SAR of the pheno-
typic active, the better the user is able to select the fragments for
pursuing. In general, the more similar the PDB fragment is to the
phenotypic active, the more predictive the binding mode is likely to
be.
When a fragment has been selected, this is matched with the
PDB ligand fragments (step 2). The PDB structures containing thishow the information workﬂow. External programs used within the platform are marked
in normal font. (For interpretation of the references to colour in this ﬁgure legend, the
iction of phenotypic screening hit molecules, Journal of Molecular
Fig. 3. Snapshots of the web-interface showing the workﬂow of the platform. Numbers correspond to the numbers of the workﬂow steps given in Fig. 1.
N. Homeyer et al. / Journal of Molecular Graphics and Modelling xxx (xxxx) xxx 5fragment are displayed. A link to the Protein Data Bank [26] enables
an easy inspection of the PDB structures that are found. When one
of the structures is selected, the cavity comparison is carried out
(step 3). The result of this step is a webpage listing those ten pro-
teins that possess the most similar binding sites to the binding site
of the selected PDB structure. These proteins can be ﬁltered by
essentiality for M. tb. survival according to DeJesus et al., 2017 [46]
and Grifﬁn et al., 2011 [47]. After selection of one of the protein
structures, the hit molecule is docked into this potential target
structure (step 4). On the results page of the docking step, the
generated complex structure is graphically displayed in amolecular
viewer. The viewer is the IcmJS [38] Java Script applet that provides
beside a number of viewing options, also possibilities tomanipulate
themolecules and to generate slides. The functionality of IcmJS [38]
is very similar to that available in the ICM Browser [38] and ICM-Pro
[48] tools used by many chemists. In addition to the visual output,
ﬁles for download are provided in many common formats so that
the users can visualize the results in their favorable visualisation
tool.
The possibility to operate the backend workﬂow via a front-end
web-interface ensures that the system is also accessible to users
with only limited computational experience.6. Case study
As a case study we analyzed ligands annotated in the TIBLE
database [49] as binders of M. tb. proteins. The TIBLE database
contains besides minimal inhibitory concentrations for compounds
againstMycobacterial species, also binding data for speciﬁc protein
targets forM. tb. [49]. For eachM. tb. target protein the ligand, with
the lowest annotated (i.e. most potent) IC50, Ki, or Kd, was selected.Please cite this article as: N. Homeyer et al., A platform for target pred
Graphics and Modelling, https://doi.org/10.1016/j.jmgm.2019.107485For some of the 106 protein targets in TIBLE [49] no ligands with
IC50, Ki, or Kd were available in the database. In total 48 protein e
ligand interactions were retrieved (see Supporting Information S5,
carried out in 2017). SMILES of the ligands were obtained from
ChEMBL [50] and used as input for the target identiﬁcation plat-
form. A complete analysis workﬂow was carried out, wherever
possible, using the default settings.7. Results
It is challenging to carry out a rigorous evaluation of the algo-
rithm. However, we chose to use examples listed in the TIBLE
database. There is enzyme inhibition data for compounds against
different enzymes in the TIBLE database. However, it is not known if
these compounds are active phenotypically against M. tb. and if so,
whether the phenotypic activity of the compounds againstM. tb. (if
any) is due to inhibition of this enzyme. The enzyme activity data
will also be dependent on the conditions under which it was
measured. Nonetheless, despite these caveats, it provides a data-
base against which to test the algorithm. For the 48 ligands that
were retrieved from the TIBLE database [49], a target prediction
analysis was performed. No target could be predicted in 16 cases,
because there were no ligands or fragments present in the PDB
database that were sufﬁciently similar to the analyzed TIBLE li-
gands. In such cases the analysis was terminated at the “Frag-
mentation” or “Fragment matching” steps (Fig. 1). These cases were
not included in the evaluation of the platform, because in a real
target search scenario a user would have identiﬁed the problem
and would not have made a target prediction based on the very
dissimilar ligands.
The remaining 32 cases were considered for performanceiction of phenotypic screening hit molecules, Journal of Molecular
N. Homeyer et al. / Journal of Molecular Graphics and Modelling xxx (xxxx) xxx6analysis. A prediction was counted as correct, when the target an-
notated in TIBLE was among the top 10 predicted targets or among
the 10 targets listed after ﬁltering to remove non-essential proteins
as deﬁned by DeJesus et al., 2017 [46]. It must be noted that the
algorithm may have also identiﬁed other proteins to which the
phenotypic actives bind, but which have not (yet) been identiﬁed as
binding partners through experimentation and that these other
molecular targets could be responsible for at least some of the
phenotypic activity.
Out of the 32 cases, a correct prediction was possible for ﬁve
ligands, where the ligand and/or the protein was not highly similar
to the ligand and/or protein from TIBLE (Fig. 4). Proteins were not
regarded as similar when the PDB protein was different from the
target protein or when the PDB proteinwas the same protein as the
target protein but from a distantly related organism. In addition to
these challenging predictions, there were nine cases where ligands
and/or proteins were similar to the ligands/proteins from TIBLE.
With respect to the protein this meant that the PDB proteinwas the
same protein as the target protein, but from a closely relatedFig. 4. Pie chart of the results of the case study analysis for 32 ligand e target protein
associations from the TIBLE database. In addition to the targets from the TIBLE data-
base the platform can predict other, so far not experimentally identiﬁed targets that
might be responsible or add to the phenotypic effect. If these targets could be taken
into account, it could increase the hit-rate of the algorithim.
Please cite this article as: N. Homeyer et al., A platform for target pred
Graphics and Modelling, https://doi.org/10.1016/j.jmgm.2019.107485organism. Ligands in this category contained, for example, the same
core as the TIBLE ligand, however, had additional substituent(s) or
similar but different functional groups. Beside these successful
target predictions there were ﬁve cases where a crystal structure of
the target protein in complex with the analyzed ligand existed. In
all of these cases the “self-search”, that is the search of the target
structure based on the same protein-ligand complex structure from
the PDB, was successful. In total the percentage of the 19 successful
cases sums up to 60%.
There were 13 cases where the platform failed to provide a
correct prediction (although of course there could be other targets
that the algorithm predicted, but have not yet been identiﬁed
experimentally). For three of the studied targets there were no PDB
or model structures in the in-house M. tb. structure database. Such
cases cannot be recognized by the user, but cannot be prevented
either. The database currently covers ~40% of the M. tb. proteome
and will be extended as much as possible as more and more PDB
structures become available with sufﬁcient sequence similarity.
However, we decided that we would only include modelled M. tb.
structures where there is a high degree of conﬁdence.
In one case (CHEMBL1818383, Rv0467) the prediction was not
successful because the ligand in the identiﬁed PDB template
structure (PDB code: 5bta) binds at the interface to the DNA. As the
currently implemented cavity comparison methods cannot take
nucleotide molecules into account such cases cannot be handled by
the system. A user can identify such cases by looking at the binding
site of the ligand in the identiﬁed PDB structure. A direct link to the
respective PDB webpage facilitates a visual inspection of the
binding position of the ligand.
In nine cases the target could not be predicted due to reasons
that are not obvious. There can be explanations for some of these
failures (see discussion), but the user of the platformwould most of
the time not be able to identify these, because internal knowledge
of the database content is required. Therefore, these nine cases in
addition to the three cases where the target protein is not in the
M. tb. structure database need to be considered as unsuccessful
predictions.
A further complication is that often inhibitors bind to multiple
proteins. So whilst the compounds may not be predicted to bind to
the protein highlighted in TIBLE, it is conceivable that the com-
pounds may bind to other proteins in addition to those indicated in
TIBLE. Further, the phenotypic response of the pathogen may or
may not be related to inhibition of a particular enzyme.
8. Discussion
The target prediction platform presented in this manuscript has
proven to be capable of predicting the targets of ligands of M. tb.
proteins for which binding afﬁnity data are available [49]. Even if
those cases where the PDB M. tb. crystal structures for the
respective protein-ligand exist, are not considered, the prediction
was successful in 44% of the cases. On the other hand there are
37.5% of cases for which the prediction was not successful. Among
these, 9% (3 test cases) failed due to the absence of the protein
target in the database. As more and more PDB structures become
available and new M. tb. models are built based on them, it can be
expected that the number of such cases would decrease.
Among the ligands for which targets were successfully pre-
dicted, were ligands of well-known and largely studied M. tb. tar-
gets as PknB (Rv0014c), peptide deformylase (Rv0429c), Cyp51
(Rv0764c), InhA (Rv1484), ftsZ (Rv2130c), KasB (Rv2246), cysK1
(Rv2334), aroQ (Rv2537c), tmk (Rv3247c), and the reduc-
toisomerase dxr (Rv2870c), as well as the thymidylate synthases
ThyA and ThyX (Rv2764c, Rv2754c) but also ligands of relatively
unexplored targets such as the NAD kinase (Rv1695).iction of phenotypic screening hit molecules, Journal of Molecular
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reasons that were not obvious. The causes for the inability of the
algorithm to predict the expected targets can be complex. While
the binding afﬁnity data in the TIBLE database prove that the li-
gands are targeting the respective proteins, it is not knownwhether
the annotated interacting protein is the primary target of the ligand
compound.
For example, for CHEMBL1762028 the target Rv1106c (cifB)
annotated in TIBLE was not found (Fig. 5). However, the platform
identiﬁed M. tb. Cyp125 (Rv3545, PDB entry: 2x5w) as a potential
target. Indeed, there is a very similar ligand to CHEMBL1762028
bound to this target in the PDB. Therefore, Cyp125 is likely an
alternative target of CHEMBL1762028. The identiﬁcation of Rv1106c
is likely hampered by the absence of structures of the cifB protein in
complex with a similar ligand. The database comprises threemodel
structures of cifB, all of which contain NAD as bound ligand. As the
CHEMBL ligand has no similarity with NAD, it likely binds at a
different binding site that is not annotated in the system and could
therefore not be identiﬁed in the cavity comparison.
In the case of CHEMBL1446150, the target annotated in TIBLE
was Rv1284, a b-carbonic anhydrase. This target was not identiﬁed
in our algorithm. However, a M. tb. crystal structure of the O-
phosphoserine sulfhydrylase (Rv1336) in complex with a ligand
similar to the CHEMBL compound was found. There are four PDB
structures and one modelled structure of Rv1284 in the M. tb.Fig. 5. Target search for CHEMBL1762028 (ligand of Rv1106c, cifB). Workﬂow on top and on
that are available in the database.
Please cite this article as: N. Homeyer et al., A platform for target pred
Graphics and Modelling, https://doi.org/10.1016/j.jmgm.2019.107485structure database. All of these are apo structures, where the an-
notated binding sites are less certain.
A case where the reason for the failure is less clear is
CHEMBL608841, which is annotated as inhibiting salicyl-AMP
ligase (Rv2384, MbtA) in TIBLE. Here a crystal complex structure
of the peptide arylation enzyme of Acinetobacter baumannii (PDB-
entry: 3o83) was identiﬁed as template for cavity comparison. Both
the 3D structure of the protein and the bound ligand are similar to
the target models and the ChEMBL ligand respectively. The model
structures of the target (Rv2384) in the M. tb. structure database,
shows a sufﬁciently large 3D similarity with the PDB template
structure, and seven of them have similar ligands bound to the
same binding site as the PDB template protein. It is therefore not
obvious why Rv2384 is not found as a potential target. One reason
for this could be that the aliphatic side chain moiety of the ligand in
the template PDB structure (PDB-entry: 3o83), that is absent in the
ligands of the model M. tb. structures, prevents a correct detection
of the binding site of the target protein. A correct identiﬁcation of
the target might also be hampered by the fact that the PDB tem-
plate structure does not cover the whole sequence of the peptide
arylation enzyme of A. baumannii, so that the C-terminus adopts a
structure inwhich it comes in close contact with the binding site. In
line with this the results indicate that most likely the differences
between the binding sites of the PDB and the target structures are
still too large to detect the similarity and the target binding site isthe right side shows the analysis steps. The table on the bottom left lists the structures
iction of phenotypic screening hit molecules, Journal of Molecular
N. Homeyer et al. / Journal of Molecular Graphics and Modelling xxx (xxxx) xxx8lost in the noise especially from unspeciﬁc apo pocket binding sites.
Consistent with our expectations we generally have observed
that apo pockets are relatively seldom identiﬁed as correct target
binding sites and seem rather to contribute noise to the cavity
comparison step. This is probably the case, because the whole
pockets and not only the regions where a ligand would potentially
bind have been used for the deﬁnition of the binding sites.
Despite the different levels of data certainty and some minor
drawbacks (such as non-protein targets, proteins for which a reli-
able homology model could not be prepared), the platform has
overall proven to be capable to predict the targets of ligands for
which binding data were available in the TIBLE database with a
reasonable success rate (see Fig. 4). It can therefore be expected
that the platform is also able to be useful in the prediction of the
targets of phenotypically active compounds. A great advantage of
the platform is that the associated data and the backend database
can easily be updated, so that it will be possible to keep the system
up to date and consider the large amount of additional PDB struc-
tures that become newly available each month. In the future we
plan to improve some aspects of the platform as the apo pocket
deﬁnition and the chemical space available for fragment matching.
9. Conclusions
We have developed a computational method for predicting the
targets of phenotypic hits inM. tb. On test cases, the algorithm has a
good success rate in predicting the target of phenotypic hits.We see
this as a hypothesis generating tool, which needs to be followed up
experimentally. There are several factors to bear in mind here.
There are some drugs which do not target proteins, and these will
not be identiﬁed by this approach. Many drugs actually bind to
multiple proteins, some of which, but not necessarily all, are
responsible for the phenotypic effect. Some or all of these will be
predicted by the algorithm. Therefore, in our test data, some pre-
dicted targets may look like false positives, but actually may be
binding partners. A limitation of the algorithm is the dependence
on high quality models of theM. tb. proteins. This will expand over
time. However, certain protein classes are not well represented,
such as membrane proteins. Another challenge is that the chemical
space of the PDB ligands does not reﬂect all of the space of the
phenotypic hits. Despite all these caveats, the algorithm is
remarkably good at identifying potential drug targets. A further
beneﬁt of the algorithm is that it also can predict a binding mode of
the molecule in the target, which has great value in compound
optimisation. However, as with all modelling, it is important that
the user recognizes that this platform is hypothesis generating and
needs to be conﬁrmed experimentally.
Much drug discovery for infectious diseases is carried out using
phenotypic screening, owing to the lack of highly validated drug
targets. The lack of highly validated targets is in part due to an
incomplete understanding of the biology of the pathogens; what
are the physiologically relevant key pinch points. In many cases it is
not known whether it is possible to inhibit an enzyme with a
compound that has the correct (oral) drug-like properties. Other
factors are also important such as the rate of kill of the organism
and the degree (percentage) by which a target must be inhibited to
have a pharmacological effect. As discussed above, in some cases
there are also issues such as compound penetration, metabolism
and efﬂux.
The work reported here has focused on developing the platform
for tuberculosis. However this could be extended to other patho-
gens, by changing the database of proteins. This would require
extracting protein structures from the protein databank, for the
pathogen of interest, and making high quality models where there
were no experimental structures.Please cite this article as: N. Homeyer et al., A platform for target pred
Graphics and Modelling, https://doi.org/10.1016/j.jmgm.2019.107485Declaration of competing interest
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